Literature DB >> 23745173

Evaluation of Tumor Cell Response to Hyperthermia with Bioluminescent Imaging.

Renshu Zhang1, Yanfei Zhou, Paul C Wang, Rajagopalan Sridhar.   

Abstract

BACKGROUND: Hyperthermia is used in combination with radiotherapy and/or chemotherapy in the treatment of various types of cancer. Currently, the tumor cell response to hyperthermia is determined largely based on the size reduction of tumor mass, which is insensitive.
METHODS: We tested the feasibility of bioluminescent imaging (BLI) in evaluation of the tumor cell response to hyperthermia by exposing luciferase-expressing MDA-MB-231-luc human breast cancer cells to high temperature (43 °C) for 10 minutes to 2 hours. The tumor cells were the imaged and the light signal generated by the tumor cells was quantified with BLI. To validate its usefulness, the light signal intensity was comparatively analyzed with the tumor cell clonogenicity and cell viability, which were measured with classic clonogenic and MTT assays.
RESULTS: The light signal intensity determined by BLI was closely correlated with the absolute number of viable cells as well as the cell viability measured with the traditional MTT assay under normal culture condition. Relative to the clonogenicity of tumor cells after exposure to hyperthermia, however, BLI underestimated, while MTT assay overestimated the cell viability. Difference in the interpretation of tumor cell clonogenic ability following hyperthermia with BLI, MTT dye, and clonogenic assay may be due to the different mechanisms of the three measurements as well as the fact that hyperthermia can induce cell damage at levels of both transient and permanent.
CONCLUSIONS: BLI is sensitive, convenient, and potentially valuable in the evaluation and monitoring of tumor cell response to treatments including hyperthermia.

Entities:  

Keywords:  Hyperthermia; bioluminescent imaging; breast cancer; tumor cell response

Year:  2012        PMID: 23745173      PMCID: PMC3671621     

Source DB:  PubMed          Journal:  J Basic Clin Med


  22 in total

Review 1.  Status of clinical hyperthermia.

Authors:  O Dahl; R Dalene; B C Schem; O Mella
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

2.  Molecular imaging of drug-modulated protein-protein interactions in living subjects.

Authors:  Ramasamy Paulmurugan; Tarik F Massoud; Jing Huang; Sanjiv S Gambhir
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

3.  Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models.

Authors:  Masaki Nogawa; Takeshi Yuasa; Shinya Kimura; Junya Kuroda; Kiyoshi Sato; Hidekazu Segawa; Asumi Yokota; Taira Maekawa
Journal:  Cancer Lett       Date:  2005-01-20       Impact factor: 8.679

4.  Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2.

Authors:  Silvia Miret; Els M De Groene; Werner Klaffke
Journal:  J Biomol Screen       Date:  2005-11-28

5.  Comparison of alamar blue and MTT assays for high through-put screening.

Authors:  R Hamid; Y Rotshteyn; L Rabadi; R Parikh; P Bullock
Journal:  Toxicol In Vitro       Date:  2004-10       Impact factor: 3.500

6.  Neutral red uptake and clonogenic survival assays of the hyperthermic sensitization of tumor cells to tumor necrosis factor.

Authors:  S P Tomasovic; M Barta; J Klostergaard
Journal:  Radiat Res       Date:  1989-08       Impact factor: 2.841

7.  Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis.

Authors:  R D Zhang; I J Fidler; J E Price
Journal:  Invasion Metastasis       Date:  1991

8.  Role of ATP in the sensitivity to heat and the induction of apoptosis in mammalian cells.

Authors:  N Miyazaki; K Kurihara; H Nakano; K Shinohara
Journal:  Int J Hyperthermia       Date:  2002 Jul-Aug       Impact factor: 3.914

Review 9.  Prediction of response to drug therapy of cancer. A review of in vitro assays.

Authors:  W T Bellamy
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 10.  Heating the patient: a promising approach?

Authors:  J van der Zee
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.